Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 28
- Registration Number
- NCT04728633
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy, Philadelphia, Pennsylvania, United States
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04421378
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California, San Francisco, California, United States
🇺🇸University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center), Los Angeles, California, United States
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- General Oncology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04150042
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT03736616
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 712
- Registration Number
- NCT03722355
Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis
- Conditions
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 2
- Registration Number
- NCT03591861
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Non-Hodgkin LymphomaRefractory Transformed Indolent Non-Hodgkin LymphomaHematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2021-10-06
- Target Recruit Count
- 19
- Registration Number
- NCT03583424
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03579927
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03570983
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- VBI Vaccines Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03382977
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸The Valley Hospital - Neurosurgeons of New Jersey, Ridgewood, New Jersey, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.